KELOWNA, BRITISH COLUMBIA -- (MARKET WIRE) -- 07/19/06 -- Pheromone Sciences Corp. ("Pheromone") (TSX VENTURE: PHS) is pleased to announce that Dr. Norman Wong, M.D., F.R.C.P.©, has joined its Scientific Advisory Board ("SAB") to assist the company with its diabetes product development.

"With extensive experience in researching and treating diabetes mellitus, Dr. Wong is an important addition to our Scientific Advisory Board," stated Dr. David White, Chair of Pheromone's SAB. "His medical career has demonstrated both his commitment to the treatment of diabetes and his ability to commercialize research findings."

Dr. Wong is the co-founder of Resverlogix Corp. (TSX: RVX) and serves as the Chairman of its SAB. He is also the Director of the Libin Gene Therapy Unit and is a Professor in both the departments of Medicine and Biochemistry & Molecular Biology at the University of Calgary.

About Dr. Wong

Dr. Wong graduated from the University of Calgary, Faculty of Medicine in 1980, completed his internal medicine residency in 1983, and then received his fellowship training in endocrinology at the University of Minnesota. His research interest deals primarily with the molecular actions of hormones and specifically that related to the regulation of lipoprotein expression and pathogenesis of diabetes mellitus. He has published numerous articles in the field of diabetes research. His clinical interest encompasses patients with diabetes mellitus or thyroid disease. In addition to his current positions, he has previously held posts at the University of Calgary. as Associate Vice-President of Research and International, and Assistant Dean (Research) Faculty of Medicine.

About the Diabetes Research Project

Pheromone has recently completed a $3.2 million private placement to fund its research into an innovative treatment for Type 1 (insulin dependent) diabetes. Currently approved transplant procedures for reversing diabetes are rarely used because of the lack of suitable human organ donors and the need for patients to use immune suppressing anti-rejection drugs for the rest of their lives. Pheromone is in the process of developing a procedure to overcome these limitations by inserting into an implantable device two types of pig cells: islet cells that produce insulin compatible with humans, and Sertoli cells which will naturally protect the islet cells from attack by the body's immune system.

Using rigorous and widely accepted scientific experimentation methods, Pheromone's goal is to receive approval for this cellular therapy product from the United States Food and Drug Administration, and from other national regulatory bodies throughout the world. The research is based on several proof-of-concept studies completed by Dr. David White, Pheromone's principal researcher, and others. The Company owns the exclusive rights to over 20 patents related to the therapeutic use of Sertoli cells.

Pheromone Sciences Corp. is a biotechnology research and development company focused on commercializing medical technologies.

ON BEHALF OF THE BOARD

Dev Randhawa, CEO

Contacts:
Pheromone Sciences Corp.
Mr. Phil Morehouse
(250) 868-8177
(250) 868-8493 (FAX)
www.pheromonesciences.com